Ondine Biomedical (AIM:OBI), a developer of light-activated antimicrobial therapies to prevent hospital infections, announced positive topline results from its Phase 3 pivotal LANTERN trial on Monday.
The study met its primary efficacy endpoint, with nasal photodisinfection added to standard of care associated with an estimated 40% relative reduction in 30-day surgical site infections compared with standard of care alone.
The trial enrolled 5,188 patients across 18 hospitals in the United States and Canada, testing the treatment against a broad population undergoing major surgical procedures.
No treatment-related serious safety concerns emerged in the topline review, a profile Ondine said is consistent with more than a decade of prior clinical use and over 250,000 patient treatments performed outside the United States.
Detailed efficacy, safety and subgroup analyses remain ongoing.
Ondine plans to request a pre-New Drug Application meeting with the US Food and Drug Administration to discuss the results before pursuing a formal marketing submission.
"Surgical site infections remain a major cause of avoidable complications following surgery, while increasing antibiotic resistance makes prevention using non-antibiotic approaches increasingly important", said Carolyn Cross, chief executive of Ondine Biomedical.
The company's nasal photodisinfection technology remains unapproved by the FDA and is to investigational use in the United States.
News Intelligence what this means for the company
Ondine's nasal photodisinfection met its Phase 3 primary endpoint, cutting surgical site infections by an estimated 40% versus standard care alone in a 5,188-patient trial across North America. The company reported no treatment-related serious safety concerns and plans to engage the FDA on a path to marketing approval—a material de-risking event for a device that has been in clinical development and is already in use outside the US, but remains investigational domestically.
The Phase 3 win validates the core efficacy claim and removes the largest clinical hurdle before FDA submission. Ondine now faces regulatory and commercial execution risk, but the 40% infection reduction in a large, broad surgical population - paired with a clean safety profile - substantially improves the odds of approval and adoption in a market where antibiotic resistance is driving demand for non-antibiotic prevention.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
